The Nordic countries as a cohort for pharmacoepidemiological research.
about
Use of inhaled and oral corticosteroids in pregnancy and the risk of malformations or miscarriageCohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) studyWorkplace social capital and adherence to antihypertensive medication: a cohort studyTorsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropeImpact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: a national population cohort studyAdherence to guidelines for avoiding drug interactions associated with warfarin--a Nationwide Swedish Register StudyA combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetesAccumulation of cardiovascular and diabetes medication among apparently healthy statin initiatorsWhich Medication Is the Patient Taking at Admission to the Emergency Ward? Still Unclear Despite the Swedish Prescribed Drug RegisterUse of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from Denmark, Iceland, Norway and SwedenExtracting research-quality phenotypes from electronic health records to support precision medicineComputing limits on medicine risks based on collections of individual case reportsThe Value of Patient-Centred Registries in Phase IV Drug SurveillanceDefining upper gastrointestinal bleeding from linked primary and secondary care data and the effect on occurrence and 28 day mortalityExisting data sources for clinical epidemiology: The Danish National Database of Reimbursed PrescriptionsUse of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the Medication use among persons with Alzheimer's disease (MEDALZ-2005) studySources of European drug consumption data at a country level.Do short birth intervals have long-term implications for parental health? Results from analyses of complete cohort Norwegian register data.The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab - validation against two external data sources.Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT StudyOverview of drug data within French health insurance databases and implications for pharmacoepidemiological studies.Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.Health effects of parental deaths among adults in Norway: Purchases of prescription medicine before and after bereavement.Clinical epidemiology in the era of big data: new opportunities, familiar challenges.Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study.Existing data sources for clinical epidemiology: Aarhus University Prescription DatabaseDrug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine dataDoes good leadership buffer effects of high emotional demands at work on risk of antidepressant treatment? A prospective study from two Nordic countries.Change in antihypertensive drug prescribing after guideline implementation: a controlled before and after study.Medication adherence: a review of pharmacy education, research, practice and policy in Finland.What is Behind the Seeming Cessation of the Increase in Sleep Medicine Consumption in Finland During the Last Years?Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities.Medical databases in studies of drug teratogenicity: methodological issuesDisease identification based on ambulatory drugs dispensation and in-hospital ICD-10 diagnoses: a comparisonFrom prescriptions to drug use periods - things to notice.Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model.Validation of the danish national diabetes registerUnderuse of medication for circulatory disorders among unmarried women and men in Norway?Use of palivizumab is underestimated in the Swedish Prescribed Drug Register - implications for register-based drug studies.Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study.
P2860
Q26825323-49090BC3-6801-4B66-9376-04135545497AQ28384359-09390D22-9CB2-44CD-AF23-D9F99F09D44DQ28477035-64F286D1-99F1-46B8-BB91-C1F47D1D9D2CQ28535299-E2B5F149-3634-44C9-9599-47B652876D05Q28538635-51CDBC64-B875-455A-800D-F6281C87B9F2Q28538870-D053C0C6-D806-438D-957A-4F80A6F3A765Q28542553-89C8F336-1111-4E72-BDC1-28C3685ED48CQ28543231-E6FC075F-0373-43A5-AF17-FB6B89FF54CDQ28548201-6D050226-DC74-47E8-92CB-B41EEDBB70C2Q28551620-E9D29E8B-D75B-400A-B1C7-BE3A7D6C9C55Q28648163-28BF3CD1-1DD7-4A0A-83F9-D9C3FFF56218Q28652138-0D4B2FB7-904E-4525-9EAF-DD9A4F58D9CAQ29395899-8A56ADF9-B94A-48D1-AD30-EC8309A1CBFAQ30577329-232EDB69-31F4-4522-AB19-E55BEBFCF89BQ30579857-4577D13A-4F0A-4136-92DF-083D51055B7BQ30661806-BFCAB187-5A60-4666-B8BA-C8088AF4A8E6Q30827537-D3E196D3-27F4-4EDE-947E-07A2D6BE7A22Q30835830-A51E761F-5B37-4A28-AA32-F3FFEA4584A4Q30968297-84945FD9-2E61-4E46-AB02-28677FB4D31AQ30979187-04E3BB28-0AFF-4884-99B4-0071A25094E6Q31111099-22ABB927-83E6-4838-A341-9035F07A0294Q31146596-7AEB6100-3E75-466C-8ACC-30966F4F1F85Q33600536-56253838-91B2-4912-854A-AABF2F2F9A39Q33627674-AB8A470D-DA09-4C94-BC11-654D66F93EAAQ33647254-3174D048-A853-4F25-AEEA-CA2EE3B826E3Q33770117-C89188A9-9143-4496-9B07-4F0D99D08190Q33914501-6EC342AB-BEF7-42B4-ADCC-97B9F27954CCQ33941741-B482D75F-8257-47B4-8524-AD13F04DDC35Q33995134-AA85F87C-A18E-416C-B6EE-174BCF08B0D9Q34021626-D60191A8-F4C0-4C5C-922C-A2261D78886CQ34074150-693E220D-34B4-4524-B5B1-C5B80AF3D324Q34115208-D818CC20-2547-4E39-AA02-68FAC75EBC4AQ34144164-1281D42F-D2A1-40A9-AD28-3BFF2D25DDD5Q34493849-97DE5E35-4B20-4FF0-9D09-82ECC5423299Q34551391-2261267A-C51E-4530-B7FE-6A4F9C8D2261Q34572340-41C98C68-E229-4B68-9156-BA8AB97629DFQ34758187-269C09F3-D8F3-4D78-9D18-EA7ECCD8D2BBQ34794422-03279FF1-7FD9-4220-8A5C-D8E8B55F0F09Q34823724-E5496D04-F377-4BE3-8324-15761588778DQ34976504-85A842D6-E7F5-4829-ABC0-1538A6339842
P2860
The Nordic countries as a cohort for pharmacoepidemiological research.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Nordic countries as a cohort for pharmacoepidemiological research.
@en
The Nordic countries as a cohort for pharmacoepidemiological research.
@nl
type
label
The Nordic countries as a cohort for pharmacoepidemiological research.
@en
The Nordic countries as a cohort for pharmacoepidemiological research.
@nl
prefLabel
The Nordic countries as a cohort for pharmacoepidemiological research.
@en
The Nordic countries as a cohort for pharmacoepidemiological research.
@nl
P2093
P50
P1476
The Nordic countries as a cohort for pharmacoepidemiological research.
@en
P2093
Björn Wettermark
Jaana E Martikainen
P2860
P356
10.1111/J.1742-7843.2009.00494.X
P577
2009-12-04T00:00:00Z